Theravance Biopharma, Inc. Operating Lease Right-of-Use Assets
Theravance Biopharma, Inc. (TBPH) had Operating Lease Right-of-Use Assets of $21.93 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-11
- 2026-06-30: Operating Lease, Right-of-Use Asset $21.93M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $23.00M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $24.37M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $25.45M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $21.93M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $23.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $24.37M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $25.45M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $26.49M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $27.43M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $28.35M 10-K · filed 2026-03-23 |
| 2024-09-30 | $29.33M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $31.82M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $35.36M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $36.29M 10-K · filed 2025-03-07 |
| 2023-09-30 | $37.58M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $38.45M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $39.20M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $40.13M 10-K · filed 2024-03-01 |
| 2022-09-30 | $39.99M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $41.11M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $39.35M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $39.69M 10-K · filed 2023-03-01 |
| 2021-09-30 | $40.72M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $41.51M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $42.52M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $43.26M 10-K · filed 2022-02-28 |
| 2020-09-30 | $44.39M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $45.18M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $46.11M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $46.60M 10-K · filed 2021-02-26 |
| 2019-09-30 | $46.76M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $47.83M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $48.86M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |